- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Roselle.
Displaying page 1 of 1.
| EudraCT Number: 2015-002094-38 | Sponsor Protocol Number: 0584 | Start Date*: 2016-12-29 |
| Sponsor Name:University of Leicester | ||
| Full Title: The Effect of an SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis following insulin withdrawal in people with absolute or relative endogenous insulin deficiency | ||
| Medical condition: Type 1 and Type 3c diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-004878-17 | Sponsor Protocol Number: 0.1 | Start Date*: 2017-07-20 |
| Sponsor Name:University of Leicester | ||
| Full Title: The Effect of a SGLT2 inhibitor on Glucose flux, Lipolysis and Exercise in type 2 Diabetes | ||
| Medical condition: Type 2 diabetes. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001721-29 | Sponsor Protocol Number: SPD758-216 | Start Date*: 2005-12-05 |
| Sponsor Name:SGX Pharmaceuticals, Inc. | ||
| Full Title: An Open-Label, Single-Arm, Multi-Center, Phase II/III study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in second salvage | ||
| Medical condition: Acute Myeloid Leukemia (AML) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002513-36 | Sponsor Protocol Number: ASP-1929-301 | Start Date*: 2019-08-16 | |||||||||||
| Sponsor Name:Rakuten Aspyrian, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck ... | |||||||||||||
| Medical condition: Locoregional, recurrent head and neck squamous cell carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004890-28 | Sponsor Protocol Number: AC220-007 | Start Date*: 2014-06-18 | |||||||||||
| Sponsor Name:Daiichi Sankyo Inc | |||||||||||||
| Full Title: A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-li... | |||||||||||||
| Medical condition: Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Ongoing) IT (Completed) NL (Completed) ES (Ongoing) BE (Completed) HU (Completed) CZ (Completed) HR (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005408-13 | Sponsor Protocol Number: 2689-CL-2004 | Start Date*: 2012-09-10 | |||||||||||
| Sponsor Name:Ambit BioSciences Corporation | |||||||||||||
| Full Title: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | |||||||||||||
| Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-013093-41 | Sponsor Protocol Number: AC220-002 | Start Date*: 2010-02-05 | |||||||||||
| Sponsor Name:Ambit Biosciences Corporation | |||||||||||||
| Full Title: A PHASE 2 OPEN-LABEL, AC220 MONOTHERAPY EFFICACY (ACE) STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH FLT3-ITD ACTIVATING MUTATIONS | |||||||||||||
| Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) ES (Completed) NL (Completed) PL (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.